Johnson & Johnson is quickening the pace of development of its COVID-19 vaccine candidate by bringing forward the start of its Phase I/IIa first-in-human study from September to the second half of July.
Coronavirus Update: J&J Accelerates Vaccine Study
BASF enters the lists and a new UK study, CATALYST, gets underway.
